BioCardia, Inc. SEC filings document a clinical-stage biotechnology and medical-device business focused on cell therapies and related delivery technologies for cardiovascular and pulmonary disease. Recent Form 8-K reports cover Regulation FD disclosures and other events involving CardiAMP clinical data, FDA and PMDA regulatory interactions, the Helix transendocardial delivery catheter, and patent protection for Heart3D Fusion Imaging software.
The company’s filings also record annual operating results, research and development activity, liquidity-related financial disclosures, and Nasdaq continued-listing compliance matters. These documents frame BCDA’s public-company record around product-development programs, regulatory pathways, intellectual property, capital and listing status, risk disclosures, and corporate reporting obligations.
BioCardia, Inc. (BCDA) received Nasdaq notice that its $835,000 stockholders’ equity as of September 30, 2026 was below the $2.5 million continued-listing requirement under Nasdaq Listing Rule 5550(b)(1). The notice has no immediate effect on the listing or trading of its common stock, which continues on the Nasdaq Capital Market.
BioCardia intends to provide Nasdaq with a plan by January 4, 2027. If Nasdaq accepts the plan, it may grant an extension of up to 180 calendar days from November 20, 2026 for the company to evidence compliance. If Nasdaq does not accept the plan, BioCardia may request a hearing before a Nasdaq Hearings Panel.
BioCardia, Inc. (BCDA) reported a net loss of ($1.817 million) for the three months ended September 30, 2026, compared with ($1.483 million) a year earlier. For the first nine months of 2026, net loss was ($5.689 million), versus ($6.244 million) in the comparable 2025 period.
CEO Peter Altman said BioCardia believes its CardiAMP autologous cell therapy is on track to be the first approved minimally invasive biologic therapy for heart failure in a first world country, based on recent interactions with Japan’s Pharmaceutical and Medical Devices Agency. The company also said it aims to be able to submit its Helix transendocardial delivery platform for FDA approval in the coming months.
BioCardia, Inc. (BCDA) reported a $1.817 million net loss for the three months ended September 30, 2026, compared with $1.483 million a year earlier. For the nine months, net loss was $5.689 million versus $6.244 million. Cash and cash equivalents were $2.224 million at September 30, and operating activities used $5.114 million in the nine-month period.
Management said the cash balance was insufficient to fund planned expenditures and meet obligations beyond January 2027, plans to raise additional capital, and disclosed substantial doubt about BioCardia’s ability to continue as a going concern within one year after the statements were issued. FDA meeting minutes say the ongoing CardiAMP HF II trial may support Premarket Approval (PMA). On November 6, 2026, BioCardia reported completing with Japan’s PMDA the process concerning materials required for a regulatory application. FDA accepted a revised Helix pre-submission in October and aims to provide written feedback or hold a meeting within 70 calendar days.
BioCardia, Inc. is the issuer named in an amended beneficial-ownership report by Thomas A. Satterfield, Jr. The report lists 1,539,134 shares as beneficially owned: 1,271,165 common shares and 267,969 shares issuable upon warrant exercise. The cover page states 9.9%, rounded down; the accompanying explanation describes 9.99% as the maximum beneficial ownership allowed under the applicable blocker provisions.
All 1,040,349 warrants are subject to a provision barring exercise if it would cause beneficial ownership to exceed 9.99% of common shares outstanding after exercise. The issuer had 15,138,782 common shares outstanding as of August 11, 2026. The report states that without the blocker limit, Satterfield could be deemed to beneficially own 2,311,514 shares, or 14.29%.
BioCardia, Inc. completed its consultation process with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) concerning application materials for the CardiAMP Cell Therapy System, advancing toward submission of a marketing approval application for ischemic heart failure. Completion of the consultations is not regulatory approval; CardiAMP remains subject to PMDA review and applicable Japanese regulatory requirements.
The therapy has been evaluated in three clinical trials involving more than 200 patient procedures, including two randomized, double-blind, placebo-controlled trials. BioCardia’s stated target is to treat its first patients in Japan and realize commercial revenues in 2028.
BioCardia, Inc. (BCDA) President and CEO Peter Altman, a director, reported direct purchases totaling 500 shares of common stock. He purchased 200 shares on October 15, 2026, and 300 shares on October 16, 2026, each at a reported weighted-average price of $0.95 per share. Footnotes give trade ranges of $0.94–$0.95 for October 15 and $0.94–$0.96 for October 16. The Rule 10b5-1 plan box was unchecked.
BioCardia, Inc. (BCDA) announced that the FDA accepted its revised De Novo pre-submission package for marketing clearance of the Helix catheter, intended to deliver therapeutic and diagnostic agents. BioCardia expects FDA substantive review with written feedback, followed by a meeting to discuss approval via the De Novo pathway, this quarter.
BioCardia said the FDA reviewed an initial package in May 2026 and raised no concerns regarding the product’s safety data, performance, or compatibility with general classes of agents. The FDA confirmed and accepted the meeting minutes in August 2026; BioCardia revised and resubmitted the package in September. The company says its clinical data and safety profile include 15 clinical trials involving nearly 500 patients. Acceptance of the package is a step in the review process, not marketing clearance.
BioCardia, Inc. plans to present the design and scientific support for its CardiAMP HF II study in a poster at the Heart Failure Society of America Annual Scientific Meeting in Phoenix, Arizona, October 9–12, 2026. The study aims to determine the efficacy of high-dose autologous cell treatment for patients with ischemic HFrEF who remain on guideline-directed medical therapy but have elevated biomarkers of heart stress. The presentation will be available through the Scientific Publications section of BioCardia’s website.
BioCardia says FDA has approved a category B designation for the CardiAMP cell therapy system in three separate clinical trials, based on either resolved underlying questions of safety and effectiveness or a determination that the device type can be safe and effective. The company also reports that FDA recently agreed the ongoing CardiAMP HF II trial may be sufficient to support FDA approval.
BioCardia, Inc. (BCDA) completed a revised De Novo pre-submission to FDA’s Center for Devices and Radiological Health under its Q-Submission program for the Helix Catheter, which is intended to deliver therapeutic and diagnostic agents to the heart. The revision incorporates FDA advice from a May 2026 meeting; in August 2026, FDA confirmed and accepted the meeting minutes as summarized by BioCardia.
FDA agreed there are two pathways for Helix marketing clearance and raised no concerns regarding its safety data, device performance, or compatibility with general classes of agents. BioCardia cited clinical data and safety experience from 15 clinical trials involving nearly 500 patients. Independent FDA clearance could expand partnership opportunities with developers of investigational therapies requiring targeted delivery to the heart.
BioCardia, Inc. President and CEO Peter Altman purchased 1,000 shares of common stock on September 29, 2026, at a weighted-average price of $1.03 per share. The trades ranged from $1.02 to $1.05 per share. His direct holdings following the purchase were 384,885 shares; no Rule 10b5-1 plan is reported.